Related Experiment Videos
AI-Enabled Real-World Evidence in Oncology: A Statistical Perspective for Regulatory Decisions
Lei Gao1, Dai Feng2, Binbing Yu3
1Moderna Inc., Cambridge, MA, USA. lei.gao@modernatx.com.
Abstract:
Artificial intelligence (AI) has the potential to strengthen real-world evidence (RWE) for regulatory decision-making, but its contribution varies by application and methodological maturity. RWE remains limited by challenges in data quality, population selection, treatment characterization, outcome assessment, and statistical methodology. Machine learning and generative AI (genAI), combined with causal inference frameworks, may address these challenges. We review applications, limitations, including reproducibility, bias, transportability, uncertainty quantification, and regulatory acceptability, and methodological priorities for fit-for-purpose AI-enabled RWE.
Related Concept Videos
Cancer Survival Analysis
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
Clinical Trials: Overview
Treatment Resistent Cancers
Clinical Trials
There are four phases in a clinical trial. A phase one...